Gubra A S (GUBRF) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Gubra A/s.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.330 -- 00:00:05.736 Welcome to the conference call. For the first part of the conference call, the participants 00:00:05.736 -- 00:00:10.362 will be in listen-only mode. During the questions and answers session, participants are 00:00:10.362 -- 00:00:15.629 able to ask questions by dialing pound key five on their telephone keypad. 00:00:15.629 -- 00:00:18.112 Now I will hand the conference over to the speakers. 00:00:18.112 -- 00:00:20.572 Please go ahead. 00:00:20.655 -- 00:00:24.871 Good morning. Welcome to the Huber investor presentation. 00:00:24.871 -- 00:00:28.176 My name is Markus Rohrwild, I am the CEO of Gubra. 00:00:28.176 -- 00:00:33.983 I'm joined here by our chief financial officer, Christian, 00:00:33.983 -- 00:00:39.471 our chief scientific officer, Luise, our chief medical and development 00:00:39.471 -- 00:00:44.999 officer, Thomas, the head of Gubra Ventures, Zoe, and the head of the Gubra 00:00:44.999 -- 00:00:47.021 COO, Trine. 00:00:47.021 -- 00:00:52.188 I will present an overview about the company and then we will move into the 00:00:52.188 -- 00:00:54.723 individual units. 00:00:54.723 -- 00:00:59.689 Just as a reminder, GUPRA is a disease agnostic tech biocompany, 00:00:59.689 -- 00:01:04.775 and we have deep expertise in peptide therapeutics and preclinical research 00:01:04.775 -- 00:01:06.775 services. 00:01:06.777 -- 00:01:08.720 Starting 2006, 00:01:08.720 -- 00:01:10.482 we will operate 00:01:10.482 -- 00:01:14.687 in three independent but synergistic business units. 00:01:14.687 -- 00:01:20.434 First, our GUPRA biotech unit, where we discover and develop 00:01:20.434 -- 00:01:23.427 peptide therapeutics to clinical proof of concept. 00:01:23.427 -- 00:01:26.308 our key value driver. 00:01:26.571 -- 00:01:32.017 Second, ...